Literature DB >> 2304155

Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors.

L Giuliani1, C Giberti, G Martorana, S Rovida.   

Abstract

We studied 200 consecutive patients with renal cell carcinoma who underwent radical nephrectomy and extensive lymphadenectomy. Of the patients 25% already had distant metastasis at operation. Higher T stages tended to be associated with positive nodes (p less than 0.01) and distant metastasis (p less than 0.001). However, in patients with stage N0M0V0 tumors we found no statistically significant difference in survival in relationship to the T stage of the disease (5-year survival: stage T1 80%, stage T2 68% and stage T3 70%). Of all patients 10% had positive nodes without distant metastases and no venous spread of the tumor, and the 5-year survival rate was 52%. The 5-year survival rate of patients with distant metastases was 7%. Patient survival in the presence of a vena caval tumor thrombus is similar to that of patients with distant metastases. Based on our results the different stages in disease progression may be classified as having a good prognosis--intracapsular tumors (stages T1 to T2, N0M0V0) and tumors with involvement of perirenal fat (stage T3N0M0V0), an intermediate prognosis--tumors with nodal metastases alone (stages T1 to T3, N1 to 2, M0V0) and a poor prognosis--tumors with venous invasion and/or distant metastases. Histological grading and size of tumor can be used to assess prognosis but are not more accurate than pathological staging.

Entities:  

Mesh:

Year:  1990        PMID: 2304155     DOI: 10.1016/s0022-5347(17)39992-5

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  25 in total

1.  Multiple primary tumors: 17 cases of renal-cell carcinoma associated with primary tumors involving different steroid-hormone target tissues.

Authors:  F Di Silverio; A Sciarra; G P Flammia; M Mariani; A De Vico
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 2.  Tumors of the kidney, ureter, and bladder.

Authors:  W A See; R D Williams
Journal:  West J Med       Date:  1992-05

3.  High incidence of asymptomatic brain lesions in metastatic renal cell carcinoma.

Authors:  E K Seaman; S Ross; I S Sawczuk
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 4.  Multi-modal treatment for metastatic renal cancer: the role of surgery.

Authors:  Paul Russo
Journal:  World J Urol       Date:  2010-04-04       Impact factor: 4.226

Review 5.  [Operative treatment of renal cell carcinoma].

Authors:  A Heidenreich
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

6.  Trends and outcomes of lymphadenectomy for nonmetastatic renal cell carcinoma: A propensity score-weighted analysis of the National Cancer Database.

Authors:  Nicholas J Farber; Zorimar Rivera-Núñez; Sinae Kim; Brian Shinder; Kushan Radadia; Joshua Sterling; Parth K Modi; Sharad Goyal; Rahul Parikh; Tina M Mayer; Robert E Weiss; Isaac Y Kim; Sammy E Elsamra; Thomas L Jang; Eric A Singer
Journal:  Urol Oncol       Date:  2018-11-13       Impact factor: 3.498

7.  Radical surgery for renal-cell carcinoma: caval neoplastic excision, adrenalectomy, lymphadenectomy, adjacent organ resection.

Authors:  F F Marshall; G D Steinberg; C R Pound; A W Partin
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

8.  Solitary jejunal metastasis from renal cell carcinoma presenting as small bowel obstruction 19 years after nephrectomy.

Authors:  Ibrahim Ismail; Brendon Lange Neuen; Murty Mantha
Journal:  BMJ Case Rep       Date:  2015-09-14

Review 9.  [Recurrent disease in renal cell carcinoma. "Local recurrence" after kidney-sparing and radical resection].

Authors:  M Löhr; D Rohde
Journal:  Urologe A       Date:  2005-04       Impact factor: 0.639

10.  Isolated metachronous splenic metastasis from renal cell carcinoma after 5 years.

Authors:  Thiago Franchi Nunes; Denis Szejnfeld; Luciana Nakao Odashiro Miiji; Suzan Menasce Goldman
Journal:  BMJ Case Rep       Date:  2012-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.